Validation of the Khorana Score to Assess Venous Thromboembolism and Its Association with Mortality in Cancer Patients: A Retrospective Community-based Observational Experience.
cancer
deep venous thrombosis
khorana score
pulmonary embolism
thrombosis
venothromboembolism
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
29 Apr 2020
29 Apr 2020
Historique:
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
4
6
2020
Statut:
epublish
Résumé
Khorana score (KS) stratifies patients into low, intermediate, and high risk groups for venous thromboembolism (VTE). We examined the generalizability of the KS to risk of VTE and association with mortality. A retrospective cohort study was conducted at Mount Auburn Hospital, Cambridge, Massachusetts. Patients aged 18 years or older undergoing chemotherapy were included. All patients were evaluated for a six-month period. Primary study endpoints were VTE or mortality. Some 277 participants were included with a mean age of 63.95 (standard deviation, SD ± 12.47). The incidence proportion was 6.13% and a total of 17 VTE events were reported over a 2.5-year period. Compared to those with a low KS (0), those with a high KS (3 or above) had 6.4 times (p=0.032) while with an intermediate KS (1-2) had 2.6 times the odds of having a VTE event (p=0.22). Those who had a VTE had 4.03 times the odds of death compared to those who did not have a VTE (p=0.006). Compared to those with a low KS, those with a high KS had 5.7 times (p=0.02) the odds of six-month mortality and 5.04 odds (p=0.001) of mortality at any time. High KS was associated with increased odds of VTE and mortality in our study.
Identifiants
pubmed: 32489737
doi: 10.7759/cureus.7883
pmc: PMC7255532
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e7883Informations de copyright
Copyright © 2020, Ahmed et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Best Pract Res Clin Haematol. 2009 Mar;22(1):9-23
pubmed: 19285269
Oncologist. 2018 Feb;23(2):247-255
pubmed: 28951500
Blood. 2008 May 15;111(10):4902-7
pubmed: 18216292
Circulation. 2003 Jun 17;107(23 Suppl 1):I17-21
pubmed: 12814981
Cureus. 2020 Apr 29;12(4):e7883
pubmed: 32489737
Thromb Res. 2016 Apr;140 Suppl 1:S178
pubmed: 27161693
Thromb Res. 2017 Feb;150:30-32
pubmed: 28002757
Med Oncol. 2017 Dec 4;35(1):5
pubmed: 29209847
Gynecol Oncol. 2019 Mar;152(3):605-611
pubmed: 30616901
Oncologist. 2016 Jul;21(7):861-7
pubmed: 27125754
J Thromb Haemost. 2016 Sep;14(9):1773-8
pubmed: 27273134
J Thromb Thrombolysis. 2014 Jul;38(1):32-8
pubmed: 24154915
Ann Oncol. 2010 May;21 Suppl 5:v274-6
pubmed: 20555096
Haematologica. 2019 Jun;104(6):1277-1287
pubmed: 30606788
Clin Appl Thromb Hemost. 2018 Nov;24(8):1347-1351
pubmed: 29806470
J Clin Oncol. 2011 Mar 10;29(8):986-93
pubmed: 21282540
Res Pract Thromb Haemost. 2019 Jan 28;3(2):226-233
pubmed: 31011706
Support Care Cancer. 2013 May;21(5):1481-6
pubmed: 23430009
Cancer. 2012 Jul 15;118(14):3468-76
pubmed: 22086826